Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Operating Expenses (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Operating Expenses for 4 consecutive years, with $33.8 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 53.89% to $33.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $120.3 million through Dec 2025, up 20.52% year-over-year, with the annual reading at $120.3 million for FY2025, 20.52% up from the prior year.
  • Operating Expenses hit $33.8 million in Q4 2025 for Taysha Gene Therapies, down from $34.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $56.5 million in Q4 2022 to a low of $19.8 million in Q4 2023.
  • Historically, Operating Expenses has averaged $29.6 million across 4 years, with a median of $26.7 million in 2023.
  • Biggest five-year swings in Operating Expenses: crashed 64.85% in 2023 and later skyrocketed 53.89% in 2025.
  • Year by year, Operating Expenses stood at $56.5 million in 2022, then plummeted by 64.85% to $19.8 million in 2023, then grew by 10.6% to $22.0 million in 2024, then surged by 53.89% to $33.8 million in 2025.
  • Business Quant data shows Operating Expenses for TSHA at $33.8 million in Q4 2025, $34.0 million in Q3 2025, and $28.7 million in Q2 2025.